Talis Biomedical (Talis Biomedical) 3-Year EBITDA Growth Rate : 19.20% (As of Dec. 2023)

View and export this data going back to 2021. Start your Free Trial

What is Talis Biomedical 3-Year EBITDA Growth Rate?

Talis Biomedical's EBITDA per Share for the three months ended in Dec. 2023 was $-7.82.

During the past 3 years, the average EBITDA Per Share Growth Rate was 19.20% per year. During the past 5 years, the average EBITDA Per Share Growth Rate was 18.90% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.

During the past 6 years, the highest 3-Year average EBITDA Per Share Growth Rate of Talis Biomedical was 19.20% per year. The lowest was 3.10% per year. And the median was 12.90% per year.

Competitive Comparison of Talis Biomedical's 3-Year EBITDA Growth Rate

For the Medical Devices subindustry, Talis Biomedical's 3-Year EBITDA Growth Rate, along with its competitors' market caps and 3-Year EBITDA Growth Rate data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Talis Biomedical's 3-Year EBITDA Growth Rate Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Talis Biomedical's 3-Year EBITDA Growth Rate distribution charts can be found below:

* The bar in red indicates where Talis Biomedical's 3-Year EBITDA Growth Rate falls into.

Talis Biomedical 3-Year EBITDA Growth Rate Calculation

This is the 3-year average growth rate of EBITDA per Share. The growth rate is calculated using exponential compounding based on the latest four year annual data.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.

Talis Biomedical (NAS:TLIS) 3-Year EBITDA Growth Rate Explanation

EBITDA per Share is the amount of Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) per outstanding share of the company's stock.

Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) is what the company earns before it expenses interest, taxes, depreciation and amortization.

Talis Biomedical 3-Year EBITDA Growth Rate Related Terms

Thank you for viewing the detailed overview of Talis Biomedical's 3-Year EBITDA Growth Rate provided by GuruFocus.com. Please click on the following links to see related term pages.

Talis Biomedical (Talis Biomedical) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Talis Biomedical Corp (NAS:TLIS) » Definitions » 3-Year EBITDA Growth Rate

Comparable Companies

Traded in Other Exchanges

N/A

Address

3400 Bridge Parkway, Redwood City, CA, USA, 94065

Website

https://talisbio.com

Talis Biomedical Corp is engaged in developing and commercializing products designed to enable molecular testing for infectious diseases and other conditions at the point-of-care. Its Talis One System is a molecular diagnostic platform developed to enable point-of-care testing for infectious diseases such as COVID-19.

Executives

Andrew A Lukowiak	officer: President, other: Chief Scientific Officer	1639 WINDEMERE DRIVE, SAN MARCOS CA 92078
Heinrich Dreismann	director	320 WAKARA WAY, SALT LAKE CITY UT 84108
Rebecca Markovich	officer: Interim CFO	CARS.COM INC., 300 S. RIVERSIDE PLAZA, SUITE 1000, CHICAGO IL 60606
Raymond Cheong	director	860 WASHINGTON STREET, 3RD FLOOR, NEW YORK NY 10014
Felix Baker	director, 10 percent owner	BAKER BROS. ADVISORS LP, 860 WASHINGTON STREET 3RD FLOOR, NEW YORK NY 10014
Baker Bros. Advisors Lp	director, 10 percent owner	860 WASHINGTON STREET, 3RD FLOOR, NEW YORK NY 10014
Julian Baker	director, 10 percent owner	BAKER BROS. ADVISORS LP, 860 WASHINGTON STREET 3RD FLOOR, NEW YORK NY 10014
Baker Bros. Advisors (gp) Llc	director, 10 percent owner	860 WASHINGTON STREET, 3RD FLOOR, NEW YORK NY 10014
Baker Brothers Life Sciences Lp	director, 10 percent owner	860 WASHINGTON STREET, 3RD FLOOR, NEW YORK NY 10014
L.p. 667,	director, 10 percent owner	860 WASHINGTON STREET, 3RD FLOOR, NEW YORK NY 10014
Brian J Blaser	director, officer: President and CEO	561 CIRCLE LANE, LAKE FOREST IL 60045
Ramesh Ramakrishnan	officer: Sr. Vice President, R&D	230 CONSTITUTION DRIVE, MENLO PARK CA 94025
Randal W Scott	director	171 MAIN STREET #225, LOS ALTOS CA 94022
Jeryl L Hilleman	director	C/O INTERSECT ENT, INC., 1555 ADAMS DRIVE, MENLO PARK CA 94025
Kimberly J Popovits	director	301 PENOBSCOT DRIVE, REDWOOD CITY CA 94063